Literature DB >> 8096423

Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures.

K M Boje1, G Wong, P Skolnick.   

Abstract

Glutamate neurotoxicity was examined in cultured cerebellar granule neurons following both prolonged (20-24 h) and brief (45 min) exposure to compounds acting at strychnine-insensitive glycine receptors. Glutamate neurotoxicity was reduced in a concentration-dependent fashion by brief exposure to the glycine partial agonists 1-aminocyclopropanecarboxylic acid (ACPC) and (+-)-3-amino-1-hydroxy-2-pyrrolidone (HA-966) and the competitive antagonist, 7-chlorokynurenic acid (7-CK) with a rank order efficacy: 7-CK > HA-966 > ACPC. Neither D-cycloserine (D-CS) nor glycine affected neurotoxicity produced by maximum glutamate concentrations, while glycine but not D-CS augmented the effects of submaximum glutamate concentrations. Prolonged exposure of cultures to either full (glycine) or partial agonists (ACPC, D-CS, HA-966) abolished the neuroprotective effects of ACPC and significantly diminished the neuroprotective effects of HA-966. In contrast, the neuroprotective effects of 7-CK were only marginally reduced by prolonged exposure to glycinergic ligands, while the neuroprotection afforded by compounds acting at other loci on the NMDA receptor complex (e.g. 2-amino-5-phosphonopentanoate (APV) and dizocilpine (MK-801)) were unaltered. These effects may represent homologous desensitization of the NMDA receptor complex at its strychnine-insensitive glycine receptor induced by prolonged exposure to glycinergic agonists and partial agonists. Nonetheless, levels of the NMDA receptor subunit zeta 1 mRNA were unaffected by prolonged exposure to ACPC, indicating the apparent desensitization could involve a post-translational modification of the NMDA receptor complex.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096423     DOI: 10.1016/0006-8993(93)91239-o

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

Review 1.  Pharmacological enhancement of drug cue extinction learning: translational challenges.

Authors:  K M Kantak; B Á Nic Dhonnchadha
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine.

Authors:  Stefan G Hofmann; Mark H Pollack; Michael W Otto
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 3.  Neurological and neuropsychological consequences of electrical and lightning shock: review and theories of causation.

Authors:  Christopher J Andrews; Andrew D Reisner
Journal:  Neural Regen Res       Date:  2017-05       Impact factor: 5.135

4.  Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor.

Authors:  G Olmos; N DeGregorio-Rocasolano; M Paz Regalado; T Gasull; M Assumpció Boronat; R Trullas; A Villarroel; J Lerma; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

5.  Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain.

Authors:  Jennifer K Forsyth; Peter Bachman; Daniel H Mathalon; Brian J Roach; Robert F Asarnow
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

6.  Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.

Authors:  K M Boje; S S Lakhman
Journal:  Neurochem Res       Date:  1998-09       Impact factor: 3.996

7.  D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

Authors:  JoAnn Difede; Judith Cukor; Katarzyna Wyka; Megan Olden; Hunter Hoffman; Francis S Lee; Margaret Altemus
Journal:  Neuropsychopharmacology       Date:  2013-11-12       Impact factor: 7.853

8.  Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.

Authors:  Donald C Goff; Corinne Cather; Jennifer D Gottlieb; A Eden Evins; Jared Walsh; Lisa Raeke; Michael W Otto; David Schoenfeld; Michael F Green
Journal:  Schizophr Res       Date:  2008-09-16       Impact factor: 4.939

9.  Glutamatergic agents for OCD and related disorders.

Authors:  Christopher Pittenger
Journal:  Curr Treat Options Psychiatry       Date:  2015-09

Review 10.  Enhancing exposure-based therapy from a translational research perspective.

Authors:  Stefan G Hofmann
Journal:  Behav Res Ther       Date:  2007-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.